lncRNA TCL6 correlates with immune cell infiltration and indicates worse survival in breast cancer

Zhang, Yaqiong; Li, Zhaoyun; Chen, Mei‐Fang; Chen, Hanjun; Zhong, Qianyi; Liang, Lingzhi; Li, Bo

doi:10.1007/s12282-020-01048-5

Cited by 61 publications

(46 citation statements)

References 34 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Few studies have examined the effects of steroids, including P4, on lncRNA expression in cancer development. lncRNAs such as HOX transcript antisense intergenic RNA (HOTAIR) 35 and T‐cell leukemia/lymphoma 6 (TCL6) 36 were reported to be associated with the PR status of breast cancer, and may predict disease prognosis. lncRNAs such as metastasis‐associated lung adenocarcinoma transcript 1 (MALAT1) 37 and nuclear enriched abundant transcript 1 (NEAT1) 38 have been shown to regulate the cell cycle and influence the progression of endometrial cancer.…”

Section: Discussionmentioning

confidence: 99%

Microarray expression profiling of long noncoding RNAs in the progesterone‐treated lung cancer cells

Xie

Chen

2020

The Journal of Gene Medicine

View full text Add to dashboard Cite

Background: The increasing incidence and unique biological features of lung cancer in women has prompted renewed interest in the role of sex hormones in this disease. We previously showed that progesterone (P4) inhibited lung cancer tumorigenesis and progression. Here, we investigated the effects of P4 on expression of long noncoding RNAs (lncRNAs) and target mRNAs in lung cancer cells. Methods: We performed high-throughput microarray and bioinformatics analysis to identify differentially expressed lncRNAs and mRNAs in the untreated and the P4-treated A549 human lung cancer cells. Results: In total, 692 lncRNAs and 268 mRNAs were significantly differentially expressed in the P4-treated A549 cells compared to the untreated A549 cells (> 2-fold change, p < 0.05). Of the lncRNAs, 82 and 610 were up-regulated and down-regulated, respectively. Gene ontology, pathway and network analyses showed that many of the mRNAs were involved in the regulation of classical pathways, including Notch signaling. Differential expression of a lncRNA signature composed of NONHSAT000264, FR075921, FR324124, linc-TRIM58, RP1-93H18.7, RP11-120 K9.2, RP11-134F2.2 and NONHSAG024980 was validated by quantitatuve reverse transcriptase-polymerase chain reaction analysis. Conclusions: This is the first report of differentially expressed lncRNAs in the P4-treated lung cancer cells. The results suggest that lncRNAs could serve as potential therapeutic targets for P4-sensitive lung cancer.

show abstract

Section: Discussionmentioning

confidence: 99%

Microarray expression profiling of long noncoding RNAs in the progesterone‐treated lung cancer cells

Xie

Chen

2020

The Journal of Gene Medicine

View full text Add to dashboard Cite

show abstract

“…For instance, XIST depletion enhances the secretion of exosomal miRNA-503 to activate M1-M2 conversion of microglia, which is essential for maintaining the suppressive immune microenvironment and inhibiting T cell proliferation 138 . In addition to those lncRNAs mentioned above, multiple lncRNAs have been found to be associated with immune system regulation, including RP4-583P15.10 139 , T-cell leukemia/lymphoma 6 (TCL6) 140 , growth hormone secretagogue receptor opposite strand (GHSROS) 141 , and linc00152 142 . These findings demonstrate that lncRNAs may act as promising predictive biomarkers and therapeutic targets for BC immunotherapy.…”

Section: Lncrnas-mediated Bc Resistance In Different Clinical Scenarimentioning

confidence: 99%

Managing therapeutic resistance in breast cancer: from the lncRNAs perspective

et al. 2020

View full text Add to dashboard Cite

Breast cancer (BC) is the most common female malignancy and the second leading cause of cancer-related death worldwide. In spite of significant advances in clinical management, the mortality of BC continues to increase due to the frequent occurrence of treatment resistance. Intensive studies have been conducted to elucidate the molecular mechanisms underlying BC therapeutic resistance, including increased drug efflux, altered drug targets, activated bypass signaling pathways, maintenance of cancer stemness, and deregulated immune response. Emerging evidence suggests that long noncoding RNAs (lncRNAs) are intimately involved in BC therapy resistance through multiple modes of action. Therefore, an in-depth understanding of the implication of lncRNAs in resistance to clinical therapies may improve the clinical outcome of BC patients. Here, we highlight the role and underlying mechanisms of lncRNAs in regulating BC treatment resistance with an emphasis on lncRNAs-mediated resistance in different clinical scenarios, and discuss the potential of lncRNAs as novel biomarkers or therapeutic targets to improve BC therapy response.

show abstract

“…For instance, lncRNA-LINC00665 affects the infiltration level of macrophages and DCs, as well as suppresses Tregs and prevent T-cell exhaustion by acting as ceRNA to target FTX [ 10 ]. LncRNA-TCL6 is positively related to tumor-infiltrating lymphocytes (TILs) infiltration and immune checkpoint molecules, like PD-1, PD-L1, and CTLA-4 [ 11 ]. Oncogenic lncRNA LINK-A attenuates antigen presentation of tumor cells, which weakens immunosurveillance and facilitates cancer cells escape from immune checkpoints and survival of malignant cells [ 12 ].…”

Section: Introductionmentioning

confidence: 99%

“…LncRNA-XIST downregulation potentiates the apoptosis of polymorphonuclear neutrophils (PMNs) and dampens the formation of neutrophil extracellular trap (NET) via inhibition of IL-12A in rat model of lung transplantation [ 65 ]. In breast cancer, lncRNA-TCL6 correlates with neutrophils infiltration and manifests poor survival of cancer patients [ 11 ]. In ovarian cancer, upregulated lncRNA-HOTTIP can stimulate the production and secretion of IL-6 by regulating transcription factor c-jun, and increase the level of PD-L1 in TANs, and in turn refraining the activity of T cells, and ultimately facilitating immune escape of cancer cells (Fig.…”

Section: Introductionmentioning

confidence: 99%

Long noncoding RNA: a dazzling dancer in tumor immune microenvironment

Zhang

Liu

Liao

2020

J Exp Clin Cancer Res

View full text Add to dashboard Cite

Long noncoding RNAs (lncRNAs) are a class of endogenous, non-protein coding RNAs that are highly linked to various cellular functions and pathological process. Emerging evidence indicates that lncRNAs participate in crosstalk between tumor and stroma, and reprogramming of tumor immune microenvironment (TIME). TIME possesses distinct populations of myeloid cells and lymphocytes to influence the immune escape of cancer, the response to immunotherapy, and the survival of patients. However, hitherto, a comprehensive review aiming at relationship between lncRNAs and TIME is missing. In this review, we focus on the functional roles and molecular mechanisms of lncRNAs within the TIME. Furthermore, we discussed the potential immunotherapeutic strategies based on lncRNAs and their limitations.

show abstract

lncRNA TCL6 correlates with immune cell infiltration and indicates worse survival in breast cancer

Cited by 61 publications

References 34 publications

Microarray expression profiling of long noncoding RNAs in the progesterone‐treated lung cancer cells

Microarray expression profiling of long noncoding RNAs in the progesterone‐treated lung cancer cells

Managing therapeutic resistance in breast cancer: from the lncRNAs perspective

Long noncoding RNA: a dazzling dancer in tumor immune microenvironment

Contact Info

Product

Resources

About